A veteran of the biopharmaceutical industry with a distinguished career spanning over three decades, Osbourn is recognised for her pioneering work in antibody research and leadership across both industry and academia. Her appointment marks a strategic step forward as Alchemab advances its pipeline of preclinical antibody therapies.
Alchemab Therapeutics has appointed Jane Osbourn, the company’s Co-Founder and Chief Scientific Officer, as Chief Executive Officer and Member of the Board.
Osbourn brings over 30 years of biopharmaceutical industry experience to the role. Prior to co-founding Alchemab in 2019, she served as Vice President of Research and Development at AstraZeneca’s biologics arm MedImmune, which saw her contribute to the development of antibody phage display technology and the discovery and development of several marketed antibody therapies.
She was previously a Director of Babraham Bioscience Technologies, Cambridge Enterprise, the Crick Translational Advisory Group, as well as Chair of the Board of Directors of the UK BioIndustry Association.
Commenting on her latest appointment, Osbourn said: “I have had the great pleasure of helping to lead the company since the beginning… With several novel targets and therapeutic antibodies in preclinical development, I am delighted to lead Alchemab as Chief Executive Officer through this next phase.”
Osbourn is also currently a Venture Partner at SV Health Investors and was awarded an Order of the British Empire (OBE) and Scrip’s Lifetime Achievement Award in 2019 for her services to drug discovery, development and biotechnology.
